Stress changes the brain in ways that most people never notice until the effects show up in daily life. It can make fear feel stronger, drain motivation, and increase the risk of depression and other mental health conditions.

Scientists have spent decades trying to understand why this happens, often focusing on the brain’s systems that trigger activity and emotion.


EarthSnap

A new review suggests the answer may also depend on something much quieter: the brain’s ability to slow itself down.

Instead of looking for a new discovery, the review brings together 50 years of research to show that one small molecule, called somatostatin, may act as one of the brain’s key braking systems.

When stress interferes with that system, the circuits that control mood and behavior may begin to change.

A small molecule with a surprising history

Somatostatin was discovered by accident in 1973. Researchers were searching for a substance that would release growth hormone.

Instead, they found a tiny peptide made of 14 amino acids that did exactly the opposite by shutting growth hormone production down.

Scientists later found that somatostatin does much more than regulate hormones. Inside the brain, it works as a neurotransmitter, helping nerve cells communicate with one another while keeping brain activity under control.

The body produces two forms, SST-14 and SST-28, which act through five different receptor types. That complex system suggests restraint is just as important to healthy brain function as excitement.

The cells that keep brain activity balanced

Many of the brain cells that produce somatostatin belong to a group called inhibitory interneurons. In several brain regions, they account for nearly one-third of all interneurons.

Rather than creating bursts of activity, these cells quietly help prevent brain circuits from becoming overactive.

They also release GABA, one of the brain’s main calming chemical messengers. Together, GABA and somatostatin reduce excessive signaling between neurons.

Research has shown that disrupting these cells can increase fear, reduce pleasure-seeking behavior, and produce other changes commonly linked to mood disorders.

Brain cells that aren’t bystanders

Study co-author Dr. Hongling Guo works in the School of Chemical Biology and Biotechnology at Peking University Shenzhen Graduate School.

“What becomes visible only when you assemble the whole literature is that somatostatin neurons are not bystanders in stress,” said Dr. Guo.

“They are selectively vulnerable to it. And that vulnerability falls on the very circuits that decide mood.”

Stress leaves different marks across the brain

One important message from the review is that stress does not affect somatostatin in a single, predictable way.

Short-term stress can quickly increase somatostatin levels in parts of the brain such as the dentate gyrus.

Long-lasting stress often has the opposite effect, reducing the number of somatostatin-producing neurons in the hippocampus while animals lose interest in rewards and show behaviors associated with depression.

Stress in various brain regions

Different kinds of stress also affect different brain regions.

Predator odor, sleep loss, restraint stress, early separation from a mother, and exposure to open spaces each leave distinct patterns.

The signatures appear in areas including the amygdala, prefrontal cortex, zona incerta, bed nucleus of the stria terminalis, and septum.

Circuits matter more than individual cells

Modern neuroscience allows researchers to study individual neural connections instead of simply counting cells. That has changed how scientists view somatostatin neurons.

Rather than acting alone, these neurons serve as connection points linking several brain regions involved in emotion.

In the central amygdala, they help regulate fear by connecting with the zona incerta and the periaqueductal gray.

Within the zona incerta itself, they connect the anterior cingulate cortex and the lateral habenula, influencing whether an animal develops behaviors linked to despair or recovery.

“In our own work on the zona incerta, chronic restraint stress quieted these neurons, and switching them back on produced antidepressant-like effects,” Dr. Guo said.

“The same shape kept appearing in region after region. That is finally what made a review feel necessary.”

Biological differences emerge

The review also highlights growing evidence that chronic stress changes somatostatin neurons differently in males and females.

Studies examining individual cells found differences in genes involved in GABA production, cell signaling, glutamate receptors, acetylcholine receptors, and growth hormone signaling.

Those biological differences were also reflected in behavior.

“The sex differences run through almost every level we looked at, from the transcriptome to the behavior,” said Dr. Shupeng Li, a co-author at Tsinghua University in Shenzhen.

“Something that rescues a male animal can do nothing in a female, or the reverse. No honest therapy can ignore that.”

Clues for future treatments

Human studies have repeatedly found reduced levels of somatostatin in the brains and spinal fluid of people with depression. The decrease appears to be greater in women.

Similar shortages have also been reported in bipolar disorder, schizophrenia, Alzheimer’s disease, Parkinson’s disease, and one form of epilepsy.

Post-traumatic stress disorder stands out as an exception because somatostatin levels are often higher rather than lower.

Researchers still do not know whether these changes help cause disease, develop after illness begins, or simply occur alongside it.

The review also points to possible treatment opportunities. Fast-acting antidepressants such as ketamine and scopolamine appear to work in part through somatostatin-producing interneurons.

Several somatostatin-based drugs, including octreotide, lanreotide, and pasireotide, already exist, although they were developed to treat hormone disorders and tumors rather than stress-related brain conditions.

“We have a growing catalog of somatostatin analogs, and not one of them is approved for a stress-related disorder of the brain,” said Dr. Tahir Ali, a co-author at Peking University Shenzhen Graduate School.

“The reasons are stubbornly practical. The molecules degrade, or they cannot cross the blood brain barrier. The review names those walls instead of pretending they are doors.”

Questions that still need answers

The review does not claim to have solved the puzzle. Instead, it identifies several important questions.

Researchers still need to understand exactly how chronic stress changes somatostatin neurons over time and how these neurons communicate with non-neuronal brain cells during stress.

The experts also want to explore whether future gene-based therapies could safely target these cells in people.

The review appears in a special Festschrift issue honoring Dr. Seymour Reichlin, whose work over nearly eight decades helped shape scientific understanding of hypothalamic-pituitary regulation and inhibitory molecules such as somatostatin.

More than 50 years after its discovery, this small peptide continues to reshape how scientists think about stress, mood, and the brain.

The full study was published in the journal Brain Medicine.

—–

Like what you read? Subscribe to our newsletter for engaging articles, exclusive content, and the latest updates. 

Check us out on EarthSnap, a free app brought to you by Eric Ralls and Earth.com.

—–